Hematologic Oncology

For patients with advanced follicular lymphoma, a treatment strategy of rituximab induction was the most cost-effective approach compared with watch and wait.

Patients with early-stage Hodgkin lymphoma who have a negative PET finding after 3 cycles of chemotherapy have a good prognosis without undergoing radiotherapy.

A 62-year-old man presents with anemia and fever. A renal mass is detected and a biopsy is performed. What is your diagnosis?

Researchers have found immunologic evidence that simian virus 40 (SV40) may be associated with non-Hodgkin lymphoma (NHL).

In this review we discuss adoptive cellular immunotherapies, small-molecule inhibitors, and immunomodulatory agents. We also mention other novel therapies on the horizon.

With each passing year, chemotherapy is less and less a focus of interest. Instead, the focus is on the abundance of exciting new biologic and targeted agents that are bulldozing the therapeutic landscape in the lymphomas and chronic lymphocytic leukemia.

Results from a small study suggest that treatment with interferon alpha 2a could help chronic myeloid leukemia patients discontinue imatinib treatment.

A small retrospective study of heavily pretreated patients with chronic myeloid leukemia found bosutinib to be a good option in the fourth-line setting.

Low levels of vitamin D may be associated with poor survival in patients with follicular lymphoma, according to the results of a new analysis.

Use of routine follow-up imaging to monitor asymptomatic diffuse large B-cell lymphoma patients resulted in a small survival benefit, but at a substantial cost.

A 22-year-old man presents with enlarged axillary lymph nodes. What is your diagnosis?

Stem cell transplantation from an HLA-genoidentical sibling or an HLA-matched unrelated donor did not affect outcomes among high-risk pediatric ALL patients.

A single-arm, open-label trial in Australia found that selective early switching from imatinib to nilotinib is feasible and effective in patients with CML.

CML patients with high CIP2A levels treated with second-generation tyrosine kinase inhibitors have better outcomes than those treated with imatinib.

Results of a single-institution study found the risk for fracture among survivors of hematopoietic stem-cell transplantation increased by nearly eight times.

The next few years hold great promise, as new agents emerge and others consolidate their place on our shelves. We will be forced to rethink strategies and redefine management as a new era of immuno-oncology dawns.

Here we review monoclonal antibodies that have received FDA approval for the treatment of NHL and CLL in the last 5 years, as well as promising agents in development.

In a phase I trial, DT2219, the novel bispecific ligand-directed toxin, has shown activity against relapsed and refractory B-cell lymphoma and leukemia.

A 32-year-old man presents with malaise and fatigue. A bone marrow biopsy is performed. What is your diagnosis?

Treatment with carfilzomib and dexamethasone doubled the PFS in relapsed multiple myeloma patients compared with treatment with bortezomib and dexamethasone.

In patients with AML, post-therapy parameters including minimal residual disease and remission were found to be independent prognostic factors for outcomes.

Induction treatment for acute myeloid leukemia with amonafide L-malate/cytarabine failed to improve the rate of complete response over daunorubicin/cytarabine.

Multiple myeloma patients had better overall survival if they had prior knowledge of having monoclonal gammopathy of undetermined significance.

Researchers have identified patient factors linked with the discontinuation of ibrutinib therapy for reasons other than disease progression.

The FDA has approved panobinostat (Farydak), in combination with bortezomib and dexamethasone, for treating patients with multiple myeloma.